Friday, July 21, 2017 4:17:51 PM
Maintaining Buy rating and increasing our 12-month price target to $17.35 per share from $13.35 due to increased sector valuation and forecasted EPS growth to FY19.
SLP’s long-term growth should be driven by the increased use of software tools and consulting analytics for drug discovery, as well as the expansion, integration, and development of new products from the acquisition of Cognigen Corp. in FY15 and the 4Q17 acquisition of DILIsym Services, Inc.
On June 1, 2017 the company acquired North Carolina based DILIsym Services, Inc., a provider of drug- induced liver injury simulation software and related consulting services. In calendar 2016, DILIsym generated net earnings of approximately $720,000 on revenue in excess of $3 million.
SLP has penetrated nearly 20% of the pharmaceutical, biotechnology, and generic companies that would be potential users of its software and/or consulting services. In April 2017, an agreement with Quantum Bio Solutions of South Korea gave SLP the opportunity to sell its software tools to at least 40 new organizations.
3Q17 EPS (reported 7/10/17) was $0.12 per share, on a 12.2% rise in sales to $6.7 million. We forecasted sales of $6.5 million and EPS of $0.11. In the year-ago period, SLP reported EPS of $0.11 on sales of $6 million
We increase our FY17 sales and EPS forecasts to $22.9 million (prior was $22 million) and $0.32 per share (prior was $0.31) due to 3Q17 results and the anticipated 4Q17 contribution from the acquisition of DILIsym.
For FY18, we increased by $0.04 per share our EPS projection to $0.40 on sales growth of 19% to $27.2 million (prior was $24.2 million) due to a full year contribution from DILIsym.
In FY19, we project EPS of $0.48 per share on sales growth of 10.5%. Our accelerated EPS growth forecast reflects an increase in software customers and consulting services reaching at least 33% of total sales.
See the full report at:
http://www.taglichbrothers.com/companyreports/simplus/simplus-07192017.pdf
The only place where success comes before work is in the dictionary
Recent SLP News
- Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date • Business Wire • 10/09/2024 08:06:00 PM
- Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings • Business Wire • 10/08/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2024 08:34:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 08:30:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/01/2024 08:29:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/27/2024 08:24:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:45:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:11:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:09:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:29:04 PM
- Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • Business Wire • 08/28/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 12:00:21 PM
- Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions • Business Wire • 08/23/2024 12:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/08/2024 06:18:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:25:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:24:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:22:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:19:09 PM
- Simulations Plus Releases DILIsym® X • Business Wire • 08/01/2024 12:30:00 PM
- Simulations Plus Releases ADMET Predictor® Version 12 • Business Wire • 07/30/2024 12:30:00 PM
- Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum • Business Wire • 07/25/2024 12:30:00 PM
- Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety • Business Wire • 07/11/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/08/2024 12:56:32 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM